Proteomic Study of Urinary Stone Disease

Urinary Proteomic Profiling Using ProteinChip SELDI-TOF-MS: A Potential Means of Identifying Protein Biomarkers of Urinary Stone Formers

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00199459

Enrollment

Registered

2005-09-20

Start date

2005-01-31

Completion date

2008-11-30

Last updated

2009-09-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Calculi, Hyperoxaluria, Urinary Calculi

Keywords

calculi, proteomics

Brief summary

Urinary protein levels are not routinely measured in stone patients while there is strong evidence that proteins play a role in the etiology of stones. The purpose of this study is to examine the urinary and serum proteins of stone formers compared to healthy subjects utilizing the high throughput method, Surface Enhanced Laser Desorption/Ionization (SELDI). We hypothesize that there is a unique set of proteins expressed in serum and urine in stone patients that can be detected by SELDI. Ultimately, this will better our understanding of stone disease and help develop new prevention strategies.

Detailed description

Urinary stone disease affects 10% of the Canadian population during their lifetime and approximately half of these patients will have another episode within ten years. Currently, patients undergo metabolic testing (serum and 24 hour urine tests) to identify modifiable risk factors; however, no modifiable risk factors are identified in many patients, yet they continue to form stones. New techniques must be developed to identify stone patients at risk for future recurrences and ultimately to develop more specific prevention strategies. Urinary protein levels are not routinely measured in stone patients while there is strong evidence that proteins play a role in the etiology of stones. The purpose of this study is to examine the urinary and serum proteins of stone formers compared to healthy subjects utilizing the high throughput method, Surface Enhanced Laser Desorption/Ionization (SELDI). We hypothesize that there is a unique set of proteins expressed in serum and urine in stone patients that can be detected by SELDI. Once a protein is identified as a biomarker, a specific assay similar to a quick and affordable dipstick test may be developed to identify those stone patients at risk of future stones. Ultimately, this will better our understanding of stone disease and help develop new prevention strategies. Comparisons: protein profiles (serum/urine) of stone patients both during the presence of a stone and 6 weeks after they have passed it. comparison of stone profiles of stone patients with controls (non-forming stone patients).

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* Controls: * Ages 18 to 65 years of age * No history of stone disease and no radiographical evidence of stone (as demonstrated by negative ultrasound) * No family history of stones * Healthy and no autoimmune or systemic disease that may affect renal function (see

Exclusion criteria

) Stone patients * Ages 18 to 65 years of age * Solitary stone of any size, in any location along the urinary tract (except lower renal calyceal stones and bladder stones) * Radiology of any modality proving the existence of the stone (ultrasound, computed tomography, intravenous pyelogram, kidney-ureter-bladder x-ray)

Countries

Canada

Outcome results